Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TBI-302 |
| Synonyms | |
| Therapy Description |
TBI-302 is a hemoglobin-drug conjugate that comprises hemoglobin linked to floxuridine, which delivers floxuridine to the liver potentially resulting in decreased tumor growth (Journal of Clinical Oncology 2016 34:15_suppl, e14061). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TBI-302 | TBI 302|TBI302 | TBI-302 is a hemoglobin-drug conjugate that comprises hemoglobin linked to floxuridine, which delivers floxuridine to the liver potentially resulting in decreased tumor growth (Journal of Clinical Oncology 2016 34:15_suppl, e14061). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03908840 | Phase I | TBI-302 | Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma | Unknown status | USA | 0 |